A new anti-aging drug is about to hit the market. A new range of drugs which are termed as Senolytics might prevent health issues caused by aging cells. Sometimes the old cells get toxic by the surrounding tissues. This ultimately leads to several health problems.
Senolytics can attack specifically the aging and the harmful cells. One of the critical health issues caused by toxic aging cells is idiopathic pulmonary fibrosis (IPF). The health problem is caused by cell senescence. This ultimately leads to scars on lung tissues. This can lead to life risks.
Couple of drugs has been already approved by Food & Drug Administration (FDA) Authorities. These medicines can treat IPF. These drugs are respectively pirfenidone and nintedanib. These drugs do not provide satisfactory results in treating IPF. The survival rate for IPF is approximately 3 to 5 years.
IPF is a fibrotic disease of the luns. This health issue is generally detected in people above the age of 60 years. The information on IPF and its survival rate has been provided by Dr. Anoop Nambiar. He is an associate professor at the University of Texas Health Science Center at San Antoni. He is also the founding director of the Interstitial Lung Disease Program of the University of Texas.
Dr. Anoop and his team members conducted clinical trial of 2 new drugs, dasatinib and quercetin. The experiment was carried out in coordination with the Mayo clinic. These drugs were earlier approved by FDA for treating other diseases. The drugs have been tested in human beings. Results of the research have been published in the EBioMedicine journal. This Lancet Publication contains further details of the study.
In this experiment, 14 participants consumed the medicine orally. The medicine course was for 3 consecutive days in a week. The medicine was given for 3 weeks. At the part of the clinical test, physical function of the participants was observed. Participants were asked to furnish details of symptoms every week. The researchers also looked into aspect of safety of the drugs.
Darlene is a master of science and makes her a person rich in scientific histories. She is an editor and an employee of the organization. With her deep knowledge of science, Darlene is doomed to the habit of explaining all the examples of science. Her desire to learn and discover makes her an ingenious work-woman on the floor. she has huge contribution to the organization for Science column.